438187

Lovastatin, Sodium Salt

InSolution ≥95%

• Sinónimos: InSolution Lovastatin, Sodium Salt
• Fórmula empírica (notación de Hill): C₂₄H₃₇O₆ · Na
• Peso molecular: 444.54
• Código UNSPSC: 51111800
• NACRES: NA.77

Propiedades

• Nivel de calidad: 100
• Análisis: ≥95% (HPLC)
• formulario: liquid
• fabricante / nombre comercial: Calbiochem^®
• condiciones de almacenamiento: OK to freeze; avoid repeated freeze/thaw cycles; protect from light
• Condiciones de envío: dry ice
• temp. de almacenamiento: −70°C

Descripción

Descripción general

Carboxylate form of Lovastatin (Cat. No. 438185) that is active in whole cells and cell-free assays. Lovastatin is reported to be an anti-hypercholesterolemic agent that acts as a reversible competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocks a series of biological events including activation of p21^ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21^ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF.

Carboxylate form of Lovastatin (Cat. No. 438185) that is active in whole cells and cell-free assays. Lovastatin is reported to be an anti-hypercholesterolemic agent that acts as a reversible competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocks a series of biological events including activation of p21^ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21^ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF.

Acciones bioquímicas o fisiológicas

Cell permeable: yes

Primary Target
HMG-CoA reductase

Reversible: yes

Envase

Packaged under inert gas

Advertencia

Toxicity: Harmful (C)

Forma física

A 10 mM (5 mg/1.13 ml) solution of Lovastatin, Sodium Salt (Cat. No. 438186) in H₂O.

Reconstitución

Following initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 6 months at -70°C.

Otras notas

Rao, S., et al. 1999. Proc. Natl. Acad. Sci. USA96, 7197.
Carel, K., et al. 1996. J. Biol. Chem.271, 30625.
McGuire, T.F., et al. 1996. J. Biol. Chem.271, 27402.
Umetani, N., et al. 1996. Biochim. Biophys. Acta1303, 199.
Xu, X.Q., et al. 1996. Arch. Biochem. Biophys.326, 233.
Reusch, J.E.-B., et al. 1995. J. Biol. Chem.270, 2036.

Información legal

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Código de clase de almacenamiento: 12 - Non Combustible Liquids
• Clase de riesgo para el agua (WGK): nwg
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable